Technology | April 14, 2010

Wrap Helps Reduce Pacemaker, Defibrillator Infections


April 14, 2010 – An antibacterial wrap for implanted pacemakers and defibrillators released this week is designed to provide protection against infections. The AigisRx Flat delivers the antimicrobial agents rifampin and minocycline. "The current AigisRx envelope provides potent antimicrobial protection and also anchors the device to prevent device migration. However, in patients who are undergoing battery change-outs, using the AigisRx Flat option helps minimize dissection of the pre-existing pocket,” said Heather Bloom, M.D., assistant professor of medicine, Emory University School of Medicine, director, cardiac electrophysiology services, Atlanta Veterans Affairs Medical Center. “Since the risk of infection is much higher in change-outs, partially due to the vascular pocket preventing tissue penetration by oral antibiotics, having a drug-eluting device on the site is of critical importance." Hospitalization for device infection increased faster than rates of device implants from 1996 through 2006, according to the National Hospital Discharge Survey, conducted by the Centers for Disease Control and Prevention. This was further reinforced in the January 2010 guideline issued by the American Heart Association and the Heart Rhythm Society, which explicitly states there is a significant unmet clinical need in device-related infection. Following commercial release in 2008, Aigisrx envelope has been implanted in more than 8,500 patients nationwide. For more information: www.TYRX.com


Related Content

News | EP Lab

April 22, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home April 29, 2025
Home
News | EP Lab

April 21, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, will ...

Home April 21, 2025
Home
News | EP Lab

Feb. 12, 2025 — Orchestra BioMed Holdings, a biomedical company accelerating high-impact technologies to patients ...

Home February 14, 2025
Home
News | EP Lab

July 31, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home July 31, 2024
Home
News | EP Lab

July 17, 2024 — BioCardia, Inc., a company focused on cellular and cell-derived therapeutics for the treatment of ...

Home July 17, 2024
Home
News | EP Lab

June 25, 2024 — Heart Hospital of New Mexico at Lovelace Medical Center (HHNM) and GE HealthCare (announced HHNM as the ...

Home June 25, 2024
Home
News | EP Lab

May 30, 2024 — Stereotaxis, a pioneer in surgical robotics for minimally invasive endovascular intervention, announced ...

Home May 30, 2024
Home
News | EP Lab

May 21, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home May 21, 2024
Home
News | EP Lab

February 2, 2024 — GE HealthCare (Nasdaq: GEHC) announces the latest innovation in electrophysiology (EP), the Prucka 3 ...

Home February 02, 2024
Home
News | EP Lab

January 11, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of ...

Home January 11, 2024
Home
Subscribe Now